APICA: Difference between revisions

>David Hedlund
*[https://isomerdesign.com/PiHKAL/explore.php?id=4705 APICA (Isomer Design)]
>David Hedlund
{{SummarySheet}}
Line 1: Line 1:
{{SubstanceBox/APICA}}
{{SubstanceBox/APICA}}
{{SummarySheet}}


'''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis|cannabis-like]] effects when [[routes of administration|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref>
'''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis|cannabis-like]] effects when [[routes of administration|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref>
Retrieved from "http://psy.st/wiki/APICA"